TY - JOUR
TI - Insights on Multiple Myeloma Treatment Strategies
AU - Mateos, M.-V.
AU - Ludwig, H.
AU - Bazarbachi, A.
AU - Beksac, M.
AU - Bladé, J.
AU - Boccadoro, M.
AU - Cavo, M.
AU - Delforge, M.
AU - Dimopoulos, M.A.
AU - Facon, T.
AU - Geraldes, C.
AU - Goldschmidt, H.
AU - Hájek, R.
AU - Hansson, M.
AU - Jamroziak, K.
AU - Leiba, M.
AU - Masszi, T.
AU - Mendeleeva, L.
AU - O'Dwyer, M.
AU - Plesner, T.
AU - San-Miguel, J.F.
AU - Straka, C.
AU - Van De Donk, N.W.C.J.
AU - Yong, K.
AU - Zver, S.
AU - Moreau, P.
AU - Sonneveld, P.
JO - Hemasphere
PY - 2019
VL - 3
TODO - 1
SP - null
PB - Ovid Technologies (Wolters Kluwer Health)
SN - null
TODO - 10.1097/HS9.0000000000000163
TODO - antineoplastic agent, autologous stem cell transplantation;  cancer diagnosis;  cancer recurrence;  cancer risk;  clinical practice;  consolidation chemotherapy;  human;  induction chemotherapy;  maintenance chemotherapy;  minimal residual disease;  multiple myeloma;  priority journal;  relapse;  Review;  risk assessment;  smoldering multiple myeloma
TODO - The introduction of new agents and management strategies over the past decade has resulted in a major step change in treatment outcomes with deepening responses and increased survival for patients with multiple myeloma. In daily clinical practice, healthcare professionals are now faced with challenges including, optimal treatment sequencing and changing treatment goals. In light of this, a group of experts met to discuss diagnostic and treatment guidelines, examine current clinical practice, and consider how new clinical trial data may be integrated into the management of multiple myeloma in the future. © 2018 the Author(s). Published by Wolters Kluwer Health, Inc.
ER -